Dec. 12 at 3:17 PM
$ABVX "Heads up alert! Only three days until Upcoming earnings on Monday, 12/15/2025 for
$ABVX
Bullish (8.4)
Abivax (ABVX) is currently experiencing significant momentum in the market, driven largely by its promising developments in the treatment of ulcerative colitis with its lead candidate, obefazimod.
The stock has surged an impressive 1,193.96% year-to-date, reflecting strong investor interest and confidence in the company's potential.
Key financial metrics indicate a robust growth trajectory; the company has achieved substantial annual revenue growth, which is a positive indicator of its operational health.
The recent upgrade to a Zacks Rank #2 (Buy) further underscores the bullish sentiment surrounding ABVX's earnings prospects.
Comparatively, the biotech sector has been volatile, but Abivax's performance sets it apart from peers like Catalyst Pharmaceutical (CPRX), which have not experienced similar gains.
The company's P/E ratio remains competitive within the sector, suggesting that it may still be undervalued relative to its growth potential.
Looking ahead, Abivax is approaching a pivotal year with its upcoming earnings report, where analysts are optimistic about the potential for positive results based on the company’s recent trial data.
Historical performance shows that the company has exceeded expectations in past quarters, contributing to a favorable analyst consensus estimate for the upcoming report.
The anticipated results could further solidify investor confidence and potentially lead to an upward revaluation of the stock.
The overall performance of the biotech sector has been mixed, but Abivax's standout results and advancements position it favorably against its competitors, making it a stock to watch closely in the coming months.
- Funds were net buyers of
$ABVX during the previous reporting quarter.
- Funds with large holdings in
$ABVX include:
- Adage Capital P, MV:
$83MM. New position. Fund Rank: 88%
www.adagecapital.com
- Baker Brothers Advisors LP, MV:
$74MM. New position. Fund Rank: 77%
- BVF Partners LP, MV:
$47MM. New position. Fund Rank: 80%
www.bvflp.com
- Catalio Capital Management LP, MV:
$14MM. New position. Fund Rank: 56%
- Apis Capital Advisors LLC, MV:
$9MM. New position. Fund Rank: 66%
www.apiscapital.com
- Last 10 days performance: 16%
- Last 30 days performance: 29%
- Last 90 days performance: 58%
Some of the latest news articles:
- Title: 2 Under-the-Radar Stocks That Have Soared This Year
Publication Date: 12/9/2025 10:05:00 PM, Source: yahoo
URL: https://www.fool.com/investing/2025/12/09/2-under-the-radar-stocks-that-have-soared-this/?.tsrc=rss
- Title: The 1,300% Biotech Shockwave That Turned
$500 Million Into
$8 Billion
Publication Date: 12/4/2025 5:54:40 PM, Source: yahoo
URL: https://finance.yahoo.com/news/1-300-biotech-shockwave-turned-175440948.html?.tsrc=rss
- Title: Europe’s Biotech Standout Faces Crucial Year After 1,300% Rally
Publication Date: 12/4/2025 5:00:00 AM, Source: yahoo
URL: https://finance.yahoo.com/news/europe-biotech-standout-faces-crucial-050000231.html?.tsrc=rss
- Title: Assessing Valuation: ABIVAX (ENXTPA:ABVX) Shares Surge 57% Over 90 Days
Publication Date: 11/16/2025 4:07:04 PM, Source: yahoo
URL: https://finance.yahoo.com/news/assessing-valuation-abivax-enxtpa-abvx-160704287.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
